522 results about "Rash" patented technology

The availability of high quality imagers on smartphones and other portable devices facilitates creation of a large, crowd-sourced, image reference library that depicts skin rashes and other dermatological conditions. Some of the images are uploaded with, or later annotated with, associated diagnoses or other information (e.g., “this rash went away when I stopped drinking milk”). A user uploads a new image of an unknown skin condition to the library. Image analysis techniques are employed to identify salient similarities between features of the uploaded image, and features of images in this reference library. Given the large dataset, statistically relevant correlations emerge that identify to the user certain diagnoses that may be considered, other diagnoses that may likely be ruled-out, and / or anecdotal information about similar skin conditions from other users. Similar arrangements can employ audio and / or other physiologically-derived signals. A great variety of other features and arrangements are also detailed.

A once-a-day oral milnacipran modified release formulation has been developed. The formulation comprises an extended release dosage unit (optionally containing the immediate release portion) coated with delayed release coating. The milnacipran composition, when administered orally, first passes through the stomach releasing from zero to less than 10% of the total milnacipran dose and then enters the intestines where drug is released slowly over an extended period of time. The release profile is characterized by a 0.05-4 hours lag time period during which less than 10% of the total milnacipran dose is released followed by a slow or extended release of the remaining drug over a defined period of time. The composition provides in vivo drug plasma levels characterized by Tmax at 4-10 hours and an approximately linear drop-off thereafter and Cmax below 3000 ng / ml, preferably below 2000 ng / ml, and most preferably below 1000 ng / ml. The composition allows milnacipran to be delivered over approximately 24 hours, when administered to a patient in need, resulting in diminished incidence or decreased intensity of common milnacipran side effects such as sleep disturbance, nausea, vomiting, headache, tremulousness, anxiety, panic attacks, palpitations, urinary retention, orthostatic hypotension, diaphoresis, chest pain, rash, weight gain, back pain, constipation, vertigo, increased sweating, agitation, hot flushes, tremors, fatigue, somnolence, dyspepsia, dysoria, nervousness, dry mouth, abdominal pain, irritability, and insomnia.

The invention describes a method of producing extracts from the seeds of meadowfoam, brassicas and crambe plants. A number of subsidiary processes and steps are shown in order to extract differing fractions of oil. Products produced from the above method are also described including uses and methods of these products which include a variety of skin conditions including eczema, facial eczema, dermatitis, external ulcers, welts, rashes, insect bites, allergic reactions and other irritations, burns, wounds, psoriasis, acneiform eruptions, dryness, dry skin, irritation, skin atrophy, secondary infections and the like. The extracts are also described as being a useful compound for treatment of the symptoms of such skin conditions as described above. In particular the use and extraction of glucosinolate (GSL), thiocyanates (TCL) and isothiocyanates (ITCL) is described.

We present, in exemplary embodiments of the present invention, novel systems and methods for syndromic surveillance that can automatically monitor symptoms that may be associated with the early presentation of a syndrome (e.g., fever, coughing, sneezing, runny nose, sniffling, rashes). Although not so limited, the novel surveillance systems described herein can be placed in common areas occupied by a crowd of people, in accordance with local and national laws applicable to such surveillance. Common areas may include public areas (e.g., an airport, train station, sports arena) and private areas (e.g., a doctor's waiting room). The monitored symptoms may be transmitted to a responder (e.g., a person, an information system) outside of the surveillance system, such that the responder can take appropriate action to identifying, treat and quarantine potentially infected individuals, as necessary.

The availability of high quality imagers on smartphones and other portable devices facilitates creation of a large, crowd-sourced, image reference library that depicts skin rashes and other dermatological conditions. Some of the images are uploaded with, or later annotated with, associated diagnoses or other information (e.g., “this rash went away when I stopped drinking milk”). A user uploads a new image of an unknown skin condition to the library. Image analysis techniques are employed to identify salient similarities between features of the uploaded image, and features of images in this reference library. Given the large dataset, statistically relevant correlations emerge that identify to the user certain diagnoses that may be considered, other diagnoses that may likely be ruled-out, and / or anecdotal information about similar skin conditions from other users. A great variety of other features and arrangements are also detailed.

The invention provides a polypeptide composition for skin whitening and spot relieving. The polypeptide composition comprises an MC1-R antagonist (namely an alpha-MSH competitive antagonist) and / or a composition of polypeptides inhibiting alpha-MSH expression and / or a tyrosinase inhibitor. The polypeptide composition can reduce the generation of melanin, and contributes to skin brightening, so as to achieve the purposes of relieving color spots (chloasma, butterfly rash, freckle and the like), improving sallow tone and whitening skin. The concentration of each polypeptide is 0.0001-5%. The polypeptide composition provided by the invention can be prepared into various beauty and skin-care products as well as medical products.

The invention relates to a shower gel. The shower gel provided by the invention is prepared from green and safe surfactants, namely tea saponin and alkyl glycoside, safe and mild surfactants, namely lauramidopropylamine oxide, soap of potassium aliphatate and cationic guar gum, assistants, namely sucrose fatty acid ester (a foam stabilizing and thickening agent) and aloe extraction solution, and other safe assistants, such as ethylenediamine tetraacetic acid disodium salt, a preservative and deionized water. Compared with an existing shower gel product, the shower gel provided by the invention has the advantages of reasonable formula, very rich raw material sources, property of belonging to renewable resources and no toxic or side effects to human bodies, and the shower gel is green, ecological and environment-friendly, and can relieve dry and tight feeling of skin, effectively inhibit itching, nourish and moisturize the skin, enable the skin to be tender, smooth and elastic by long-term use, realize the effects of sterilizing, inhibiting bacteria, diminishing inflammation and relieving itching and realize an auxiliary treatment effect on rash and prickly heat.

Dermatological conditions / afflictions such as rosacea, common acne, seborrheic dermatitis, perioral dermatitis, acneform rashes, transient acantholytic dermatosis, and acne necrotica miliaris, most notably rosacea, are treated by topically applying onto the affected skin area of an individual in need of such treatment, a topical pharmaceutical composition which comprises a thus effective amount of ivermectin.

One aspect of the present invention relates to a covering member for a protruding portion of a patient's body. This cover is flexible and collapsible so that it conforms to the shape of the encased portion of the body. This prevents the cover from being noticed while it is worn under clothing. The cover can contain a medicament or agent for pretreating a portion of the body before an examination or procedure. When the cover is used to apply a topical anesthetic to a portion of the body for a recommended period of time prior to the procedure or examination commencing, the amount of discomfort experienced by the patient can be significantly reduced compared to the amount experienced by the patient who has the anesthetic applied for just a few moments before the procedure begins. Alternatively, the cover can be used to hold a medicament or agent on the intended portion of the body in order to heal a wound or cure a condition such as a skin rash or the like.

The present invention provides an absorbent article capable of suppressing rash of skin in regions which come into contact with a gather portion of the absorbent article, by applying a water-soluble skin care agent and oily skin care agent on the gather portion to be contacted with the skin of a wearer in wearing the absorbent article, and allowing at least a part of the above mentioned oily skin care agent to be transferred to the skin of a wearer when wearing before the above mentioned water-soluble skin care agent is transferred to the skin of a wearer.

A composition for topical treatment of dermatitis is provided. The composition includes one or more anti-histamines or a pharmaceutically acceptable salt thereof; one or more polysaccharides; and one or more Group 1, 2, or 13 metal hydroxides. The dermatitis may be a poison ivy, poison oak, poison sumac, diaper rash, eczema, lichen simplex chronicus, rashes, dermatoses, seborrheic dermatitis, psoriasis, atopic dermatitis, or the combination thereof A method of treatment of dermatitis is also provided.

The invention discloses vehicle equipment for controlling the rash advance at the tail end of a route. The vehicle equipment comprises a positioning module, a calibration module, a speed acquisition module, a calculation module, a judging module, and a braking output module; the positioning module is used for obtaining the satellite positioning of a vehicle, the calibration module is used for positioning and calibrating the satellite positioning and the actual location of the vehicle when the vehicle speed is at zero; the speed acquisition module is used for real-time acquisition of the current speed of the vehicle and using the current speed as the calculation speed; the calculation module is used for calculating the distance of the vehicle currently apart from the end and the distance of braking corresponding to the current velocity; the judging module is used for determining whether the difference between the distance of the vehicle currently apart from the end and the distance of braking is less than the preset safety margin; the braking output module is used for issuing a braking instruction to a braking system when the difference between the distance of the vehicle currently apart from the end and the distance of braking is smaller than the preset safety margin. The invention also discloses a method for controlling the rash advance at the tail end of the route. By the adoption of the vehicle equipment for controlling the rash advance at the tail end of the route, the positioning precision is high, the structure is simple, the maintenance cost is low, and the requirements of a test route can be met.